Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA)

Aref Al-Kali, Devendra Hiwase, Maria R Baer, Peter Greenberg, Jake Shortt, Robert Collins, David P Steensma, Amit Verma, Gail J Roboz, Jamile M Shammo, Oliver G Ottmann, John Francis Seymour, Jeffrey Szer, Wolfgang Meyer, Patrick Simon Zbyszewski, Michael E Petrone, Steven M Fruchtman, Guillermo Garcia-Manero, Lewis R Silverman